Acetyl-L-Carnitine
Best-in-class: Carnityl
The brain-penetrant form of carnitine that shuttles fatty acids into mitochondria for energy and supports acetylcholine — studied for cognition and mood.
Acetyl-L-Carnitine quick facts
| Suggested dose | 500–1,500 mg daily, earlier in the day. |
| How often | Daily |
| Who it's for | Cognitive, mood and mitochondrial-energy support; older adults. |
Genuine trial evidence in age-related cognitive decline, diabetic and chemotherapy-induced neuropathy, and depression in older adults — a broader clinical base than most nootropics. The neuropathy data is the strongest. It can be stimulating enough to disrupt sleep if taken late. Anyone with a seizure history should be cautious, and it is a poor idea in hypothyroidism where it may interfere with thyroid hormone action.
How Acetyl-L-Carnitine actually works
Carnitine with an acetyl group attached, which lets it cross the blood-brain barrier where plain carnitine cannot. Once there it does two jobs: it shuttles fatty acids into neuronal mitochondria for oxidation, and it donates its acetyl group to form acetyl-CoA, which is the direct precursor for acetylcholine synthesis. So it is simultaneously a mitochondrial and a cholinergic agent.
Where to get Acetyl-L-Carnitine
Buy Carnityl at Thorne →The evidence for Acetyl-L-Carnitine
Graded by what exists behind each claim.
✅ Clinically validated
- RCTs show benefit for age-related cognitive decline and mild cognitive impairment.
- Meta-analysis supports improvement in depressive symptoms, especially in older adults.
- Studied for diabetic neuropathy.
📊 Correlative data
- Carnitine status declines with age and tracks with fatigue and neuropathy.
🧪 Theoretical / extrapolated benefits
- Broad neuroprotective/longevity roles follow from its mitochondrial and cholinergic actions but are still being defined.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Acetyl-L-Carnitine actually does
The acetyl group is the entire reason this molecule is not just carnitine, and it does two things carnitine cannot. Acetyl-L-carnitine crosses the blood-brain barrier far better than the free zwitterion, and it delivers an acetyl group that can be transferred to coenzyme A by carnitine acetyltransferase. Acetyl-CoA in the neuron is the immediate substrate for choline acetyltransferase, which makes acetylcholine. That is the pharmacological argument for the cognitive indication and it is a specific one.
The parent function is a shuttle and it is not about energy in general. Carnitine palmitoyltransferase 1 on the outer mitochondrial membrane swaps coenzyme A for carnitine on a long-chain fatty acid; the acylcarnitine crosses on the translocase; carnitine palmitoyltransferase 2 swaps it back inside. Without carnitine, long-chain fatty acids cannot reach beta-oxidation at all. Short and medium-chain fatty acids do not need it Alhasaniah 2023.
Its second job is buffering, and it is the one the acetyl ester is doing constitutively. The acetylcarnitine pool absorbs excess acetyl groups when acetyl-CoA production outruns citric acid cycle capacity, freeing coenzyme A and relieving inhibition of pyruvate dehydrogenase. That buffering role is why acetylcarnitine concentrations rise during exercise and why the molecule sits at the junction of fat and carbohydrate oxidation.
Getting it into a cell requires a specific transporter and that transporter has now been solved structurally. OCTN2, the sodium-dependent organic cation and carnitine transporter, concentrates carnitine intracellularly against a gradient of roughly 50-fold; the structural basis of that sodium-dependent transport has been described Davies 2025. It is saturable, which sets a ceiling on tissue loading no oral dose can pass.
And there are neurotrophic mechanisms proposed that are not about acetylcholine at all. Acetyl-L-carnitine has been reported to acetylate histones and to induce nerve growth factor receptor expression, which is the mechanistic case in the neuropathy and mood literature. Those are cell-culture and rodent observations and they have not been demonstrated in a human brain Pennisi 2020.
Cell, rodent, human — and where it stops
The surrogate here is a cognitive rating scale in a small trial, and the field has spent twenty years failing to convert it into anything larger.
The transporter and shuttle biology transfers completely. Primary carnitine deficiency from OCTN2 mutations produces cardiomyopathy, hypoketotic hypoglycemia and skeletal myopathy that responds to carnitine, and secondary deficiency in dialysis is well characterized Sugiyama 2021. Nothing about the deficiency biology is in doubt.
The cognitive evidence peaked with a meta-analysis in 2003 and has not advanced. Pooling double-blind randomized trials of acetyl-L-carnitine against placebo in mild cognitive impairment and mild Alzheimer's disease found a modest benefit on clinical scales and on psychometric tests Montgomery 2003. A critical update two decades later describes the same literature: small trials, heterogeneous endpoints, and no adequately powered modern confirmation Pennisi 2020.
The obstacle to transfer is that every one of those endpoints is a rating scale. Clinical global impression, ADAS-Cog and MMSE in small unblinded-adjacent trials are exactly the endpoints that inflate in this therapeutic area, and the field's own experience with much larger drug programs is that effects of this size do not survive.
In dialysis the outcome question was tested more carefully than anywhere else. A multicenter, single-blind, placebo-controlled trial reduced L-carnitine supplementation in hemodialysis patients and measured carnitine kinetics alongside cardiac function Sugiyama 2021, which is the design that separates a corrected biochemistry from a corrected patient.
And the underlying carnitine pool is not easy to move. A healthy person absorbs a small fraction of an oral dose, the transporter is saturable Davies 2025, and muscle carnitine content is resistant to oral loading in the absence of an insulin stimulus. So the cognitive trials were giving a molecule whose tissue delivery in the target organ was never measured Alhasaniah 2023.
Acetyl-L-Carnitine — which form, and does it matter
Acetyl-L-carnitine and L-carnitine are not interchangeable and the difference is central nervous system access. The acetyl ester is more lipophilic and is a substrate for transport across the blood-brain barrier, which is why the cognitive literature belongs to it and the muscle literature belongs to the free form or the tartrate. Using one in place of the other discards the reason to buy either.
The D-isomer is not a cheaper version, it is an inhibitor. D-carnitine competitively inhibits carnitine acetyltransferase and can precipitate a functional deficiency. Only the L-enantiomer is used, and a product that does not say L- has not specified an active ingredient Alhasaniah 2023.
The exposure numbers are unfavorable and they explain the gram-scale dose. Oral bioavailability of acetyl-L-carnitine is modest — on the order of 10 to 20 percent — because absorption relies on a saturable carrier and passive diffusion of a zwitterion is poor. Peak plasma concentration arrives at roughly 3 to 4 hours and the plasma half-life is about 4 to 6 hours. There is no cytochrome step: the molecule is hydrolyzed to carnitine and acetate by esterases, and the kidney handles disposal with an unusually efficient renal clearance that reabsorbs over 90 percent of filtered carnitine at normal plasma concentrations and dumps the surplus sharply above them Davies 2025.
That reabsorption threshold is the real ceiling. Because the tubule stops reclaiming carnitine once plasma exceeds the physiological range, a large oral dose produces a brief plasma excursion and a large urinary loss rather than a bigger tissue pool. Splitting the dose does more than raising it.
Propionyl-L-carnitine is the third ester and it belongs to a different indication. It supplies a propionyl group that enters the citric acid cycle as succinyl-CoA and has been studied for peripheral arterial disease and claudication rather than for cognition. Three esters, three literatures, one word on the front of the bottle Alhasaniah 2023.
What would have to be true, and how you would know it was not
1. Predict plasma carnitine rises and predict it says nothing about the brain. On 1 to 2 g a day, predict carnitine, total and free rises within 2 to 4 weeks and plateaus, because tubular reabsorption saturates Davies 2025. That is the marker the product owns.
2. Predict a cognitive read-out that is measurable and modest. Use MoCA or a trail making test at baseline and 12 weeks rather than a subjective impression, and predict a change smaller than the test-retest variability in a healthy adult Montgomery 2003.
3. The prediction that cuts against the product. Predict that a modern, adequately powered, double-blind trial of acetyl-L-carnitine in mild cognitive impairment returns a null result on a standardized cognitive endpoint, because the positive literature consists of small old trials and no confirmatory program has ever been completed Pennisi 2020. A well-powered positive trial would falsify this page and would be worth a great deal.
4. Predict a responder population that is identifiable by biochemistry. Predict measurable benefit in secondary carnitine deficiency — dialysis, valproate therapy, primary transporter defects — and essentially none in a person with normal plasma carnitine Sugiyama 2021. Measure total and free carnitine before deciding, not after.
5. Predict TMAO rises and decide in advance whether that matters. Carnitine is a trimethylamine-containing compound and gut bacteria liberate trimethylamine from it. Predict TMAO (trimethylamine N-oxide) rises on chronic supplementation, more in an omnivore than in a vegetarian, and treat that as a reason to measure rather than to assume Alhasaniah 2023.
What nobody has tested yet
Nobody has measured brain acetylcarnitine after oral dosing. Magnetic resonance spectroscopy can do it, the claim depends entirely on it, and no supplementation trial has reported it Pennisi 2020. That single measurement would establish whether the mechanism engages at all.
The cognitive literature has never been replicated at scale. A meta-analysis of small trials from the 1990s Montgomery 2003 remains the evidentiary high-water mark for a compound sold to millions of people. A single modern trial would resolve it either way.
The depression signal is real enough to be worth a trial and has not had one. Small randomized studies and meta-analyses have reported antidepressant effects with unusually good tolerability, and the proposed mechanism — histone acetylation at the metabotropic glutamate receptor 2 promoter — is specific and testable Pennisi 2020. Nobody has tested it in people.
And the neuropathy indication has never been separated from deficiency. Trials in diabetic and chemotherapy-induced peripheral neuropathy have reported mixed results, and none has stratified on baseline carnitine status, which is the obvious way to find out whether the compound is a nutrient or a drug in that setting Alhasaniah 2023.
Acetyl-L-Carnitine — its own safety story, not its category's
The common effects are gastrointestinal and one is social. Nausea, abdominal cramping and diarrhea at gram doses, and a fishy body odor from trimethylamine generated by gut bacteria in people whose hepatic flavin-containing monooxygenase 3 capacity is outrun. Both are dose-related and reversible.
The TMAO question is the substantive one and it is unresolved. Carnitine is metabolized by gut bacteria to trimethylamine, which the liver oxidizes to trimethylamine N-oxide, a metabolite associated with cardiovascular risk in observational work Alhasaniah 2023. Whether supplemental carnitine raising TMAO translates into risk has not been tested with an endpoint, and it is the reason this page will not recommend indefinite use in someone with cardiovascular disease.
Seizure threshold is a specific and documented concern. Increased seizure frequency has been reported in people with existing seizure disorders taking carnitine, and the interaction is worth raising with a neurologist rather than discovering.
Renal impairment changes the arithmetic entirely. Carnitine is renally cleared and accumulates when the kidney cannot dump it, which is also why dialysis patients are the population with genuine deficiency and a supervised indication Sugiyama 2021. Supplementing unsupervised in chronic kidney disease is the wrong side of that coin.
Two more interactions and one exclusion. Valproate depletes carnitine and is the classic indication for replacement. Thyroid hormone action is antagonized by carnitine at peripheral tissue in reported work, which matters in anyone on levothyroxine. And pregnancy and lactation have no supplemental safety data. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.
Sources read for this page
- Montgomery SA, et al. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. International Clinical Psychopharmacology 2003 · PMID 12598816
- Pennisi M, et al. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients 2020 · PMID 32408706
- Alhasaniah AH. l-carnitine: Nutrition, pathology, and health benefits.. Saudi J Biol Sci 2023 · PMID 36632072
- Davies JS, et al. Structural basis of sodium ion-dependent carnitine transport by OCTN2. Nature Communications 2025 · PMID 41318751
- Sugiyama M, Hazama T, Nakano K, Urae K, Moriyama T, Ariyoshi T, Kurokawa Y, Kodama G, Wada Y, Yano J, Otsubo Y, Iwatani R, Kinoshita Y, Kaida Y, Nasu M, Shibata R, Tashiro K, Fukami K. Effects of Reducing L-Carnitine Supplementation on Carnitine Kinetics and Cardiac Function in Hemodialysis Patients: A Multicenter, Single-Blind, Placebo-Controlled, Randomized Clinical Trial.. Nutrients 2021 · PMID 34073024
How you would know if it worked
Plasma carnitine is the one number that says the dose is arriving, and it is worth drawing because the people most likely to be low — vegetarians, dialysis patients, some metabolic conditions — are also the people most likely to feel something. The second number is the cost of the first: gut bacteria convert a share of any carnitine dose to TMAO, so on a long-term habit that trade is something you can see rather than guess at.
- Carnitine, Total and Free — L-carnitine or acetyl-L-carnitine 500–2,000 mg/day Retest: 12 weeks after starting supplementation.
- TMAO (Trimethylamine N-oxide) Retest: 3–6 months after dietary change.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Acetyl-L-Carnitine — safety & side effects
- Restlessness, insomnia and GI upset — take it earlier in the day.
- Raises TMAO, like choline. In people with existing cardiovascular disease this is a live question rather than a settled one.
- May increase seizure frequency in people with epilepsy. Interacts with thyroid hormone — it can reduce thyroid hormone entry into cells, so monitor if you are treated for hypothyroidism. Caution with warfarin.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Acetyl-L-Carnitine in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Acetyl-L-Carnitine
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Acetyl-L-Carnitine — frequently asked questions
What is Acetyl-L-Carnitine?
The brain-penetrant form of carnitine that shuttles fatty acids into mitochondria for energy and supports acetylcholine — studied for cognition and mood.
What is the suggested dose of Acetyl-L-Carnitine?
500–1,500 mg daily, earlier in the day. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Acetyl-L-Carnitine dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Acetyl-L-Carnitine?
Coach Cam sources Acetyl-L-Carnitine from Thorne, with 10% off auto-applied at checkout — use the buy link on this page.
Acetyl-L-Carnitine inside a finished plan
One arm of 3 Protocol Blueprints, free to read in full.
What Acetyl-L-Carnitine is used for
Acetyl-L-Carnitine appears under 4 goals in the goal router.
Related Cognitive & Mood supplements
Where this goes next
Acetyl-L-Carnitine is the cerebral metabolism arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.